CTOs on the Move


 
Freyr is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.freyrinc.com
  • 103 Carnegie Ctr Ste 300
    Princeton, NJ USA 08540
  • Phone: 908.345.5984

Executives

Name Title Contact Details

Similar Companies

ACM Global central laboratory

ACM Global central laboratory is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Incyte

Incyte is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines that will meet serious unmet medical needs in oncology and other diseases. Incyte is a company driven by innovation, and we believe that investment in cutting-edge science and the rigorous pursuit of R&D excellence can translate into new medicines for serious unmet medical needs that positively impact patients` lives. Incyte has a diverse and growing portfolio of first-in-class and best-in-class product candidates, including both small and large molecules. Incyte is headquartered in Wilmington, Delaware with operations in 10 European countries and Japan. Our more than 1,000 employees are led by distinguished executives with proven records of success. We are proud to have been recognized by Forbes as one of the World`s Most Innovative Companies for each of the past three years.

WHPM Biotech

WHPM Biotech is a Irwindale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

FoldRx Pharmaceuticals

FoldRx Pharmaceuticals is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

American Life Science Pharmaceuticals Inc

ALSP Inc. (American Life Science Pharmaceuticals, Inc.), is a privately held company based in San Diego, California, developing new small molecule drugs for treating neurodegenerative disease initially focused on traumatic brain injury and Alzheimer`s disease. Our approach is to identify key enzymes in the brain, called proteases, which produce biologically active peptides, proteins or processes that are thought to underlie the disease. We then use those enzymes as targets for screening compounds that inhibit these proteases and thereby prevent the harmful effect caused by these peptides, proteins and processes to treat the disease. By using this innovative process, our goal is to create and advance highly-effective drug development strategies and products for treating not only traumatic brain injury and Alzheimer`s disease, but other Neurodegenerative Conditions such as Huntington`s disease, Parkinson`s disease and MS, and recover quality of life for those patients and their families.